Prostate Cancer Clinical Trial
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Summary
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify those patients with early neuroendocrine transdifferentiation and who are at greater risk for poor outcomes.
Full Description
PRIMARY OBJECTIVE:
Establish the feasibility of using gallium Ga 68-DOTATATE (68Ga-DOTATATE) PET as a predictive imaging biomarker for neuroendocrine transdifferentiation in prostate cancer.
SECONDARY OBJECTIVE:
Correlate progression of disease with degree of uptake on 68Ga-DOTATATE PET examination.
OUTLINE:
Patients receive gallium Ga 68-DOTATATE intravenously (IV). Within 55-70 minutes, patients undergo PET/CT.
After completion of study, patients are followed up for at least 1 year.
Eligibility Criteria
Inclusion Criteria:
Patients with metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement
Ability to lie still for PET scanning
Patients must be able to provide written informed consent
Exclusion Criteria:
Patients less than 18 years of age
Patients without metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement
Inability to lie still for PET scanning
Patients unable to provide written informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Atlanta Georgia, 30322, United States
How clear is this clinincal trial information?
